Who was in that NAD+ heart study?

Rats given NAD+ through a vein

Zhang and colleagues tested intravenous NAD+ in rats with heart injury. They interrupted blood flow to the heart and then restored it. NAD+ reduced the area of damaged heart muscle in that experiment.

This helps explain the interest in NAD+ and the heart. It doesn’t show that infusions prevent heart attacks in people. The injury was deliberately created under controlled conditions, which is a different question from reducing someone’s everyday heart risk.

Mice given the precursor NMN

Yamamoto and colleagues studied NMN in a mouse model of interrupted and restored heart blood flow. NMN is nicotinamide mononucleotide, an ingredient used to make NAD+. It reduced heart injury in that experiment.

The mice received NMN by injection into the abdominal cavity. This wasn’t oral NMN in people or intravenous NAD+. Those details can disappear from a headline, but leaving them out changes what a reader is likely to think the study showed.

Women taking oral NMN

In a trial in prediabetic, postmenopausal women, oral NMN improved muscle insulin sensitivity over ten weeks. That means muscle responded better to insulin under the study’s testing conditions. Body composition and HbA1c, a longer-term blood-sugar marker, didn’t change.

This is a human finding about a particular metabolic response. It doesn’t show fewer heart attacks, prevention of diabetes or benefit from a compounded NAD+ injection. The study amounts page gives the amount used, with that same population and result attached.

What can we take from all three?

We have reasons for further research, rather than proof of human heart protection. A review of human NAD+ precursor studies found limited evidence of health benefits and little information from individual tissues. Adding animal results to blood measurements doesn’t fill that gap.

For a heart claim, ask whether a human study measured the outcome being promised. Was it a blood marker, a symptom or an event such as a heart attack? Those aren’t interchangeable answers, however impressive the surrounding explanation sounds.

Safety stays part of the question. Short studies leave longer use uncertain, and a compounded injection adds preparation risks. None of these findings establishes a replacement for heart care or a personal treatment plan.

The useful habit is simple: keep asking who was tested, what they received and what changed. It makes room for an encouraging finding without turning it into more than the study found. There’s plenty to be curious about already.